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a healthy cartilage tissue requires the sustained function of many
cellular processes and any decline in performance may weaken the
tissue and lead to pathology. These changes may arise because of
inherited susceptibilities and their interaction with environmental
challenges, such as trauma, obesity and ageing.
There is much evidence that many changes occur in chondrocytes
during ageing. In OA there is evidence of an age-related increase in ER
stress, which may mark a decline in secretary pathway function in
chondrocytes and could restrict their ability to maintain the tissue.
There is also evidence of increased apoptosis in OA, which may suggest
that there is an age-related decline in chondrocyte threshold for
survival. This may extend to pathways, such as those involving DNA
repair, resistance to oxidative stress, which may result in accumulated
DNA and protein damage. It may also apply to new areas of chondrocyte
biology, such as circadian clock genes, which have been detected in
chondrocytes (Boot-Handford, Qing-jun Meng, personal communica-
tion). Many circadian clocks in other biological systems show age-
related changes and such changes in chondrocytesmay lead to impaired
function. Any of these factors may be potentially damaging, because in
cartilage, in contrast with most other tissues, there are no means by
which dead or poorly performing cells can be replaced. It is this feature
that makes chondrocytes special and cartilage the tissue in the joint
most at risk of irreversible damage and loss.
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NEW GENOMIC TECHNOLOGIES FOR THE STUDY OF OA
I. Meulenbelt. LUMC, Leiden, Netherlands
Osteoarthritis (OA) is a prevalent, disabling joint disease with a consider-
able, but complex, genetic component. In order to dissect underlying
mechanisms of OA, many researchers have applied genetic genome wide
approaches or, to explore the dynamic state ofOA affected cartilage,micro
arrayRNAexpressionproﬁling. Althoughrobustﬁndingshavebeen found,
major challenges remain; current OA susceptibility SNPs explain only
a small part of the heritability, whereas, micro-array expression tech-
niques have shown to have onlya limited ability to catalogue and quantify
the transcriptome. Given the small attributable risk of current OA
susceptibility SNPs, researchers have come to the presumption that there
may be many, yet undetected, rare variants and/or unconsidered non-
genetic variation that could inﬂuence the complex etiology of OA.
The introduction of high-throughput next generation sequencing
technologies has revolutionized both genomic and transcriptomic
research. It allows whole genome and exome DNA sequencing in
addition to sensitive RNA analyses through cDNA sequencing. As such, it
eliminates a large part of the posed challenges. Considering the non-
genetic variation, especially the epigenetic variation appears to be
relevant. Epigenetic marks as reﬂected by methylation of cytosine's in
cytosine-guanine (CpG) dinucleotides are involved in processes that
require a stable control of gene expression or a selective gene-silencing.
Loss of epigenetic control may result in differential gene expression and
may underlie complex traits. Up until now, however, the studies aiming
to explore these non-genetic variations were performed with inade-
quate genome coverage or failed to measure in the relevant (diseased)
tissue. Recently for DNA methylation, a new technology has become
available that allows high throughput typing of around 500,000
metylation sites, covering around 99 percent of RefSeq genes.
Together, these new genomic technologies may provide important
additional biological insights into molecular and cellular events
commencing OA onset.
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CLINICAL PAIN SEVERITY AND EXPERIMENTAL PAIN SENSITIVITY IN
OSTEOARTHRITIS
Y.C. Lee. Brigham and Women's Hosp., Boston, MA
Pain is the most common presenting symptom of osteoarthritis and an
important outcome in most osteoarthritis intervention trials. However,
the causes of pain among osteoarthritis patients are not well-under-
stood, and studies of pain mechanisms have been limited. To date, most
studies have relied on visual analog scales of overall pain or patient-
reported pain at joint sites, but these measurements are subjective and
prone to bias. Although osteoarthritis is often deﬁned structurally by
cartilage loss and joint space narrowing, population-based studies have
indicated that the association between joint space narrowing andpatient-reported pain is weak. Recent studies, however, suggest that
correlations between structural changes and pain may be masked by
other factors, such as central pain processing mechanisms, which differ
between patients. To examine pain mechanisms, some studies have
utilized quantitative sensory testing techniques, which rely on the
application of deﬁned, noxious, experimental stimuli to determine pain
threshold and tolerance levels. These studies suggest that, compared to
pain-free controls, osteoarthritis patients are more sensitive to exper-
imental noxious stimuli at both joint and non-joint sites, indicating
diffuse hyperalgesia, characteristic of central pain syndromes. Studies
using quantitative sensory testing methods and functional neuro-
imaging have also indicated that osteoarthritis patients have impair-
ments in conditioned pain modulation, also known as descending
analgesia or diffuse noxious inhibitory controls. This talk will give an
overview of the study of pain mechanisms in osteoarthritis, focusing on
studies of experimental pain sensitivity in osteoarthritis patients, and
the implications of these studies for future research and for the
development of pain management strategies in osteoarthritis.
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NEW GUIDELINES ON PUBLISHING ANIMAL STUDIES
C.B. Little. Kolling Inst. of Med. Res., Univ. of Sydney, St Leonards, Australia
Animal models are powerful research tools that provide a critical step
not only in furthering our understanding of disease pathogenesis and
potential therapeutic intervention, but also they contribute signiﬁcantly
to the “translatability” of drug discovery projects toward clinical reali-
zation. It is scientiﬁcally incumbent upon researchers to ensure that
their experiments are well designed, controlled, powered, analyzed and
reported. In the case of research involving animal models, this is true
not only from the perspective of good scientiﬁc practice but also to
fulﬁll our responsibility for the appropriate and ethical use of animals
i.e. implementing the “3Rs”. A critical component of reduction and
reﬁnement is ensuring that animal studies are appropriately planned,
evaluated, and reported. Poor reporting is as problematic as poor
experimental design in diminishing the value and validity of any
scientiﬁc research. Recent reviews have highlighted the deﬁciencies in
reporting in many studies using animal models for a variety of diseases,
and those for osteoarthritis (OA) are no exception.
The ARRIVE guidelines were developed to provide a comprehensive
checklist (20 items) for authors to follow (1), and their use is now
a recommendation for submission of such manuscripts to OA&C.
Although the emphasis is on “reporting”, the ARRIVE and other
guidelines, should be consulted BEFORE embarking on a study using
animals, to ensure researchers control for factors that can signiﬁcantly
alter the experimental outcomes, and hamper or even invalidate the
interpretation of the data. While applicable to all animal-based studies,
the present workshop will highlight and discuss the importance of the
ARRIVE guidelines as they speciﬁcally relate to OA research (2). Addi-
tionally speciﬁc issues in statistical analysis of animal studies (e.g. small
“n”, ordinal data etc) will be reviewed. In the long term, use of these
guidelines will promote more consistent publication of animal studies,
ultimately enabling better comparisons between laboratories and
systematic reviews of the literature.
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STATE OF ART IN MANAGING HAND OSTEOARTHRITIS
L. Punzi, P. Frallonardo, C. Campana, R. Ramonda. Rheumatology Unit,
Univ. of Padova, Padova, Italy
Hand osteoarthritis (HOA) is a common disorder frequently causing
pain and impaired function with subsequent reduction in health-
related quality of life. Compared to other OA localisations, the
management of HOA may be sometimes difﬁcult, due to its great
heterogeneity. The treatment may be inﬂuenced by many factors,
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joints involved, affected site, age of patients, and occupational activities.
According with the EULAR recommendations three treatment modali-
ties can been proposed: non-pharmacological, pharmacological, and
surgical. In many patients these modalities should be combined,
tailored to individual needs and risk factors.
Although non-pharmacological therapies are important in the
management of HOA, high quality evidence is lacking. The exercise
seems useful when combined with education and joint protection.
Advice regarding the use of electrotherapy, thermotherapy, ultrasound,
TENS or laser therapy is conﬂicting, mainly due to the lack of eligible
studies. So, their inclusion in recommendations relies mainly on
consensus methods and expert opinion.
As regard as the pharmacological therapy, the most realistic aim is the
pain relief, due to limited evidence of reliable efﬁcacy in modifying
disease activity by drugs.
Among analgesics, paracetamol is considered as the ﬁrst choice and, if
successful, the preferred for long term, although evidence supporting
its use in HOA are few. In mild to moderate pain and when not many
joints are affected, topical treatments are a good option for many
aspects, including the cost effectiveness. If paracetamol or topical
NSAIDs are insufﬁcient, then the addition of opioid analgesics should be
considered, although the evidence supporting its use in HOA is poor.
In patients who respond inadequately to paracetamol or topical treat-
ments, oral NSAIDs or COX-2 inhibitor should be used in substitution or
in addition, possibly at lowest effective dose for the shortest period of
time and taking into account individual patient risk factors, including
age and comedications.
Intra-articular (IA) long-acting corticosteroid is effective for painful
ﬂares of OA, especially trapeziometacarpal joint (TMC) OA and so, it
should be considered as an adjunct to core treatment for the relief of
moderate to severe pain in people with HOA. There are contrasting
opinions on the usefulness of IA hyaluronan (HA) in all existing
recommendations. However, in two recent trials it seems more
favourable than IA steroids.
The most studied SYSADOA in HOA has been the chondroitin sulphate
(CS). In the recent 6 months RCT performed by Gabay, decrease in global
hand pain and improvement of hand function were signiﬁcantly more
pronounced in the CS than in the placebo group. This drug was also
evaluated as DMOAD, in two independent trials comparing CS with
placebo and chondroitin polysulphate (CPS) with placebo in erosive
HOA (EHOA). The results showed that over a 3-year period CS was no
more beneﬁcial than placebo, whereas CPS was more effective than
placebo in preventing radiographic progression.
The EHOA is the HOA subset deserving main attention by new treat-
ment strategies, due to its severity and poor outcome. So, anti-cytokines
biologic agents have been tested in some pilot studies using s.c. ana-
kinra, humira and IA inﬂiximab, with good results, as also conﬁrmed by
the ﬁrst RCT recently performed by Verbruggen, with Humira.
Surgery is uncommonly performed in HOA, and evidence for its effec-
tiveness is lacking. However, for HOA at the base of the thumb, evidence
does support effectiveness of surgical therapy when conventional
therapies have failed. These surgical interventions include tra-
peziectomy, arthrodesis, osteotomy, ligament reconstruction, and joint
replacement. Surgery for areas other than the thumb base is not yet
widely available as a treatment option.
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PATHOPHYSIOLOGY OF POST-TRAUMATIC ARTHRITIS
S.R. Goldring. Hosp. for Special Surgery, New York, NY
Epidemiologic studies have ﬁrmly established the association between
acute joint injury and the increased risk for the subsequent develop-
ment and progression of osteoarthritis (OA). All of the joint tissues are
susceptible to traumatic injury, including the ligaments, menisci,
articular cartilage and periarticular bone, and to some extent the
natural history of the OA process is related to the magnitude, site and
extent of the initial joint injury. However, independent of the speciﬁc
site or target tissue affected by the injury, all of the joint tissues are
eventually affected by the osteoarthritic process. Multiple mechanisms
contribute to the pathogenesis of the osteoarthritic changes after a joint
injury and although much of the attention has focused on the adverse
effects of increased joint instability and altered joint mechanics, there is
evidence that the pathogenic process in many individual is in fact
attributable to the initial acute-impact injury to the articular surfaceand in some instances the adjacent subchondral bone. These impact
injuries not onlymay disrupt the structural integrity of these tissues but
also can induce acute as well as chronic adverse effects on the survival
and functional activities of the resident cell populations. With respect to
the articular cartilage these changes include de-regulation of the
synthetic and reparative capacity of the chondrocytes, as well as the
release of potent biological mediators such as reactive oxygen species,
proteolytic enzymes and proinﬂammatory cytokines. In addition,
although OA generally is not viewed as an inﬂammatory form of
arthritis there is evidence that synovial inﬂammation not only
contributes to joint symptoms but also plays a role in the structural and
functional deterioration of joint tissues in both post traumatic OA and
other forms of OA. De-regulated chondrocyte function and the release
of biologically active chondrocyte-derived factors or products from the
cartilage extracellular matrix have been implicated in the synovial
inﬂammation, and many of the synovial derived products in turn may
adversely affect the homeostasis of the adjacent articular cartilage and
bone. Studies have shown that the risk factors for OA initiation and
progression in patients with post traumatic OA are similar to those for
idiopathic OA in that systemic host factors and local biomechanical
factors interact and that obesity, female gender, and pre-existing early-
stage OA contribute signiﬁcantly to adverse radiographic and clinical
outcomes. There remains uncertainty regarding the long-term beneﬁt
of surgical interventions with respect to prevention or slowing the
development of OA, and there is a critical need for rigorous clinical and
laboratory studies to deﬁne the factors that are responsible for joint
deterioration in patients with traumatic joint injuries and for assessing
the impact of interventions on the status of joint tissues and function.
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REGENERATIVE MEDICINE APPROACHES FOR THE TREATMENT AND
PREVENTION OF OSTEOARTHRITIS
C. De Bari. Univ. of Aberdeen, Aberdeen, United Kingdom
Osteoarthritis (OA) is the most common joint disease and is estimated
to affect more than 8 million people in the UK alone. Underlying the
disease is a loss of the normal homeostasis of the joint with progressive
breakdown of tissues including articular cartilage and subchondral
bone leading to end-stage joint destruction and failure. For the patient,
quality of life is reduced because of the loss of movement and joint pain
increases to become continuous, even at rest. OA is deﬁned as a complex
disorder with three groups of risk factors: genetic, constitutional (e.g.,
ageing and obesity) and local (e.g., secondary to mechanical load and
joint injury).
Current treatment options are limited to analgesia and physiotherapy,
and to prosthetic joint replacement for end-stage disease. Management
of OA is aimed at alleviating symptoms but current treatments do not
address the disease process itself. There is an unmet need to develop
new treatment options that could halt disease progression, at an early
stage. In this respect, regenerative medicine (including tissue engi-
neering) offers the potential for a long-term solution via biological
regeneration, repair or replacement of the degenerate joint tissues.
Pioneering approaches to biological joint resurfacing include autolo-
gous chondrocyte implantation and marrow stimulation techniques
such as microfracture. The lecture will outline possible cell-based
therapy interventions to treatment or prevention of OA, with a partic-
ular focus onto secondary post-traumatic OA. Exogenous (autologous or
allogeneic) stem cells could be injected intra-articularly into affected
joints or implanted locally into a damaged tissue, for instance into
a defect of the articular cartilage, either in suspension or in combination
with a biomaterial. Stem cells could be transplanted either after culture-
expansion or as minimally manipulated, e.g. immediately after their
puriﬁcation from their tissue sources. However, important ongoing
issues relate to identity characterization and potency assessment of the
different types of stem cells and how they can be bioprocessed with
consistency and implanted for effective repair of the damaged joint
surface and degenerate joint tissues. Using stem cells in combination
with biomaterials, there is also the potential to create ex vivo biological
joint tissues such as menisci, or even a fully biological prosthesis.
Opportunities and challenges from a research perspective will be
discussed.
The arthritic joint also demonstrates apparent repair mechanisms that
can result in aberrant formation of cartilage and bone in the form of
chondro-osteophytes. This presumes existence of endogenous stem
cells in the joint. In this regard, we recently provided data on the
